New drug could help kidney transplant patients avoid rejection

NCT ID NCT07508787

Recruiting now Disease control Sponsor: Nefro Avillion Clinical Development, LLC Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 14, 2026 · Updated 3 times

Summary

This study tests if a new drug called siplizumab can safely prevent kidney transplant rejection better than the current standard treatment. About 120 adults receiving a kidney transplant will be split into three groups: two groups get different doses of siplizumab, and one gets the standard drug. All participants will also take standard anti-rejection medicines. The study will monitor side effects and how well the kidney works for 12 months after transplant.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for END STAGE KIDNEY DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

end stage renal failure Rejection, Psychology transplant rejection prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RENAL TRANSPLANT FAILURE AND REJECTION

Contacts and locations

Locations

Cooperman Barnabus Medical Center
RECRUITING

Livingston, New Jersey, 07039, United States
Emory University Hospital
RECRUITING

Atlanta, Georgia, 30322, United States
Tampa General Hospital
RECRUITING

Tampa, Florida, 33606, United States
University of Michigan - Michigan Medicine
RECRUITING

Ann Arbor, Michigan, 48109, United States
University of Washington Medical Center
RECRUITING

Seattle, Washington, 98195, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.